GE, NBA issue tendinopathy research challenge; FDA cancels TransMedics panel meeting;

@FierceMedDev: Crime syndicates are hacking devices to steal private medical information for profit. ICYMI last week | Follow @FierceMedDev

@EmilyWFierce: calling for more regulation of lab-developed tests prior to congressional hearing today. More from the WSJ | Follow @EmilyWFierce

> GE Healthcare ($GE) and the NBA have partnered in a $1.5 million research challenge to develop innovative ways to prevent, diagnose and treat tendinopathy. More

> Self-defined "wellness" and "lifestyle healthcare" company Alpheon acquired the assets of Lensar, a maker of ophthalmic laser systems for up to $59 million in cash, stock and debt. More

> The FDA canceled the Nov. 18 panel and postponed a subsequent Nov. 19 Gastroenterology and Urology Devices Panel meeting. The Nov. 18 date was for TransMedics' Heart in a Box device that is designed to extend the life of the organ outside the body for transplant purposes. More

Biotech News

@FierceBiotech: ICYMI yesterday: J&J nabs an early OK for 'breakthrough' multiple myeloma blockbuster contender Darzalex. Report | Follow @FierceBiotech

@JohnCFierce: Catalent stops production at French plant, brings in law enforcement after it twice detects tampering. FiercePharma story | Follow @JohnCFierce

@DamianFierce: Fun reminder of pharma's insane margins: $NVS has a Map My Run ad for a multiple sclerosis drug. Item | Follow @DamianFierce

> Roche joins Novartis' billion-dollar bet on Ophthotech's eye drug. Report

> After Paris attacks, Isis Pharma finally mulls a name change. Story

> Employee No. 1: Doug Williams launches exosome R&D player Codiak Bio with $80M-plus. Article

Pharma News

@FiercePharma: Indonesia's Kalbe and South Korea's Genexine link up for biomedical work. FiercePharmaAsia report | Follow @FiercePharma

@EricPFierce: There are lots of changes going on among generics producers but here are the top players. Feature | Follow @EricPFierce

> J&J undercuts Celgene's Pomalyst with $135K-per-year Darzalex price. Report

> Can Valeant win without big price hikes? Early Addyi scripts aren't a good sign. More

> U.S. lawmakers step up drug-pricing probes, add Valeant pharmacy to their target list. Article

Pharma Manufacturing News

> Top Novartis exec in India says two plants warned by FDA completing remediation. Item

> Baxter Singapore plant gets FDA OK to produce Advate hemophilia product. More

> Valeant adds recall to long list of problems. Article

> Regulator halts Catalent production at French plant where product sabotage suspected. Report

> Four Roche plants go up for sale in move to more high-potency, targeted drugs. Story

Drug Delivery News

> NC State team: Gold nanoparticles can control the shape of DNA, RNA. Report

> Avedro bags $32M in financing to expand use of its drug delivering ophthalmology platform. More

> Egalet announces patent for its abuse-deterrence platform. Item

> Swiss scientists take a look inside 'cubosomes' for drug delivery potential. Story

> RetroSense bags $6M in funding for its viral vector gene therapy candidate for a rare eye condition. Article

Pharma Asia News

> Lee's Pharma affiliate licenses Tragara's TG02 oncology treatment for much of Asia. Story

> Indian drugmakers eye Japanese market for acquisitions. Report

> India looks to push development of biotech startups. More

> HK-based Chi-Med takes another regulatory step to Nasdaq listing. Article

> Australia's Mesoblast formally lists on Nasdaq. Item